Product Name :FGFR1 monoclonal antibody
Applications :WB, IHC, IF/ICC
Application_all :WB (1/500 - 1/1000), IHC (1/50 - 1/200), IF/ICC (1/10 - 1/50)
Background :Fibroblast growth factors (FGFs) produce mitogenic and angiogenic effects in target cells by signaling through cell surface receptor tyrosine kinases. There are four members of the FGF receptor family: FGFR1 (flg), FGFR2 (bek, KGFR), FGFR3, and FGFR4. Each receptor contains an extracellular ligand-binding domain, a transmembrane domain, and a cytoplasmic kinase domain . Following ligand binding and dimerization, the receptors are phosphorylated at specific tyrosine residues . Seven tyrosine residues in the cytoplasmic tail of FGFR1 can be phosphorylated: Tyr463, 583, 585, 653, 654, 730, and 766. Tyr653 and Tyr654 are important for catalytic activity of activated FGFR and are essential for signaling . The other phosphorylated tyrosine residues may provide docking sites for downstream signaling components, such as Crk and PLC.
Product :Mouse IgG1 kappa. Liquid in PBS, pH 7.3, 30% glycerol, and 0.01% sodium azide.
Purification&Purity :This antibody is purified through a protein G column.
Storage&Stability :Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Specificity :Recognizes endogenous levels of FGFR1 protein.
Note :For research use only, not for use in diagnostic procedure.
Pathway :Tumor Angiogenesis,ESC Pluripotency and Differentiation Signaling Pathway,Signaling Pathways Activating p38 MAP Kinase
Alternative Name :BFGFR; CEK; FGFBR; FLG; FLT2; HBGFR; Fibroblast growth factor receptor 1; FGFR-1; Basic fibroblast growth factor receptor 1; BFGFR; bFGF-R-1; Fms-like tyrosine kinase 2; FLT-2; N-sam; Proto-oncogene c-Fgr; CD331
Immunogen :KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of human FGFR1. The exact sequence is proprietary.
Modification :Unmodification
